MX2020010269A - Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa. - Google Patents

Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.

Info

Publication number
MX2020010269A
MX2020010269A MX2020010269A MX2020010269A MX2020010269A MX 2020010269 A MX2020010269 A MX 2020010269A MX 2020010269 A MX2020010269 A MX 2020010269A MX 2020010269 A MX2020010269 A MX 2020010269A MX 2020010269 A MX2020010269 A MX 2020010269A
Authority
MX
Mexico
Prior art keywords
mirikizumab
dose
ulcerative colitis
methods
maintenance
Prior art date
Application number
MX2020010269A
Other languages
English (en)
Spanish (es)
Inventor
James Benedict Canavan
Stuart William Friedrich
Kathryn Ann Krueger
Catherine Milch
Jay Lawrence Tuttle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2020010269A publication Critical patent/MX2020010269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2020010269A 2018-03-30 2019-03-28 Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa. MX2020010269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (1)

Publication Number Publication Date
MX2020010269A true MX2020010269A (es) 2020-11-06

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010269A MX2020010269A (es) 2018-03-30 2019-03-28 Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.

Country Status (29)

Country Link
US (2) US12152072B2 (https=)
EP (2) EP4327866B1 (https=)
JP (4) JP7119114B2 (https=)
KR (1) KR102552693B1 (https=)
CN (1) CN111936165A (https=)
AU (2) AU2019243283C1 (https=)
BR (1) BR112020018099A2 (https=)
CA (1) CA3095297A1 (https=)
DK (2) DK3773715T3 (https=)
EA (1) EA202091989A1 (https=)
ES (2) ES3063700T3 (https=)
FI (2) FI4327866T3 (https=)
HR (2) HRP20260275T1 (https=)
HU (1) HUE067445T2 (https=)
IL (2) IL277514B2 (https=)
LT (2) LT3773715T (https=)
MA (2) MA52216B1 (https=)
MD (2) MD4327866T2 (https=)
MX (1) MX2020010269A (https=)
MY (1) MY202368A (https=)
PL (2) PL4327866T3 (https=)
PT (2) PT4327866T (https=)
RS (2) RS67806B1 (https=)
SG (1) SG11202009526RA (https=)
SI (2) SI3773715T1 (https=)
TW (2) TWI744617B (https=)
UA (1) UA128578C2 (https=)
WO (1) WO2019191464A1 (https=)
ZA (1) ZA202005388B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
BR112022015996A2 (pt) * 2020-02-14 2022-10-11 Janssen Biotech Inc Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
TW202241506A (zh) * 2021-01-06 2022-11-01 美商艾伯維有限公司 治療克羅恩氏病及潰瘍性結腸炎之方法
BR112023024064A2 (pt) * 2021-05-20 2024-01-30 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節
US20230159633A1 (en) * 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
AU2023383916A1 (en) * 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
TW202500184A (zh) 2023-03-10 2025-01-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
CN121443635A (zh) * 2023-06-16 2026-01-30 信达生物医药科技(杭州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2452694T1 (sl) * 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.

Also Published As

Publication number Publication date
SI4327866T1 (sl) 2026-04-30
MA52216A (fr) 2021-02-17
RS67806B1 (sr) 2026-03-31
PT3773715T (pt) 2024-05-27
LT4327866T (lt) 2026-03-10
WO2019191464A1 (en) 2019-10-03
US12152072B2 (en) 2024-11-26
AU2023248103B2 (en) 2026-02-05
HRP20240904T1 (hr) 2024-10-11
ES2983809T3 (es) 2024-10-24
TWI744617B (zh) 2021-11-01
CA3095297A1 (en) 2019-10-03
HRP20260275T1 (hr) 2026-04-10
DK4327866T3 (da) 2026-02-23
ES3063700T3 (en) 2026-04-20
NZ767902A (en) 2024-05-31
IL277514B2 (en) 2024-11-01
MY202368A (en) 2024-04-24
JP2025020134A (ja) 2025-02-12
SI3773715T1 (sl) 2024-06-28
JP2022169562A (ja) 2022-11-09
ZA202005388B (en) 2025-05-28
MD3773715T2 (ro) 2024-10-31
EA202091989A1 (ru) 2021-01-13
US20250034243A1 (en) 2025-01-30
LT3773715T (lt) 2024-06-25
FI3773715T3 (fi) 2024-05-30
SG11202009526RA (en) 2020-10-29
MA52216B1 (fr) 2024-07-31
MD4327866T2 (ro) 2026-04-30
PL3773715T3 (pl) 2024-08-19
JP7331219B2 (ja) 2023-08-22
US20210032325A1 (en) 2021-02-04
AU2023248103A1 (en) 2023-11-09
BR112020018099A2 (pt) 2020-12-22
IL312807B1 (en) 2025-02-01
PL4327866T3 (pl) 2026-04-20
TW201946657A (zh) 2019-12-16
TW202206104A (zh) 2022-02-16
EP4327866A2 (en) 2024-02-28
EP4327866B1 (en) 2025-12-10
JP2023166388A (ja) 2023-11-21
JP2021517156A (ja) 2021-07-15
IL312807A (en) 2024-07-01
DK3773715T3 (da) 2024-05-27
MA67901B1 (fr) 2026-02-27
RS65661B1 (sr) 2024-07-31
IL277514B1 (en) 2024-07-01
UA128578C2 (uk) 2024-08-21
KR102552693B1 (ko) 2023-07-07
EP3773715A1 (en) 2021-02-17
AU2019243283B2 (en) 2023-07-27
PT4327866T (pt) 2026-02-17
HUE067445T2 (hu) 2024-10-28
AU2019243283A1 (en) 2020-09-24
JP7571225B2 (ja) 2024-10-22
IL312807B2 (en) 2025-06-01
FI4327866T3 (fi) 2026-02-18
JP7119114B2 (ja) 2022-08-16
IL277514A (en) 2020-11-30
TWI837532B (zh) 2024-04-01
EP3773715B1 (en) 2024-05-08
EP4327866A3 (en) 2024-03-20
CN111936165A (zh) 2020-11-13
KR20200128101A (ko) 2020-11-11
AU2019243283C1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
PE20221338A1 (es) Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
AR104771A1 (es) Inhalador de polvo seco
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
RU2016149316A (ru) Лечение ревматоидного артрита
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
RU2019107146A (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
RU2015115398A (ru) N-ацетил-L-цистеин для применения в экстракорпоральном оплодотворении
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
AR063207A1 (es) Tratamiento del dolor
NZ773583A (en) Methods of treating psoriasis
NZ781127A (en) Mirikizumab for use in a method of treating crohn’s disease
NZ767902B2 (en) Methods of treating ulcerative colitis
NZ773583B2 (en) Methods of treating psoriasis
NZ781127B2 (en) Mirikizumab for use in a method of treating crohn's disease
NZ760033A (en) Methods to treat opioid use disorder
AR102903A1 (es) Inhalador de polvo seco
AR132862A1 (es) Métodos para el tratamiento de la dermatomiositis con brepocitinib
AR130444A1 (es) Métodos para el tratamiento de infecciones virales
DOP2025000033A (es) Método de tratamiento de una enfermedad o trastorno mediado por linfocitos t portadoras del segmento trbv9 dentro del receptor de células t
UA106956C2 (uk) Спосіб лікування діабетичної ретинопатії